Sareum Holdings PLC Patent Grants in Japan & China for TYK2 Inhibitors
December 19 2017 - 1:00AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
19 December 2017
(AIM: SAR) 19 December 2017
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Patent Grants in Japan and China for Sareum's TYK2
Inhibitors
Sareum (AIM: SAR), the specialist cancer drug discovery and
development business, is pleased to announce that the Japanese
Patent Office has granted a patent for inventions associated with
Sareum's TYK2 Kinase Inhibitor Programme, and that the Chinese
Patent Office has issued notification that such a patent will be
granted subject to certain formalities being completed.
This patent* describes compounds that inhibit JAK kinase enzyme
function, in particular TYK2 kinase. It also describes the use of
these compounds in the treatment of disease mediated by these
kinase enzymes, including autoimmune diseases such as multiple
sclerosis, psoriasis and inflammatory bowel disease.
The granting of the Japanese patent and the imminent granting of
the Chinese patent mean that Sareum will have approved patent
protection in Japan and China for its TYK2 inhibitor programme.
Similar patent protection in Europe was announced on 10 November
2014 and the Company expects that similar patents will be granted
in other major markets, including the USA, in due course.
* Japanese Patent no. 6239118, Chinese Patent Application no.
201380080517X
Sareum's CSO, Dr John Reader, commented: "The granting of this
patent in Japan and China is a key step in securing the protection
of the intellectual property for our TYK2 programme in all major
markets and it enhances the value of this programme as we progress
discussions with potential licensing partners."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated
Adviser and Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7282 9571
Notes for editors:
Sareum is a specialist drug discovery and development company
delivering targeted small molecule therapeutics, focusing on cancer
and autoimmune disease, and generating value through licensing them
to international pharmaceutical and biotechnology companies at the
preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint
kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology
and in clinical trials targeting a range of advanced cancers. The
key role of Chk1 in cancer cell replication and DNA damage repair
suggests that SRA737 may have broad application as a targeted
therapy in combination with other oncology and immune-oncology
drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine
kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and
Aurora+FLT3 inhibitors in haematological cancers, which are in the
IND-enabling preclinical and lead optimisation stages.
The Company's drug discovery technology platform (SKIL(R) -
Sareum Kinase Inhibitor Library) is being applied to generate drug
research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKAPFALXFFF
(END) Dow Jones Newswires
December 19, 2017 02:00 ET (07:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024